VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
RMDResMed Inc.
$188.63$27.5B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksRMDPrice Target
RMD logo

ResMed Inc. (RMD) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 35 analysts

40.4% Below Target

RMD trades 40.4% below Wall Street's consensus target of $264.86.

Current Price$188.63
Average Target$264.86
Target
Current
Low$225.00
Median$265.00
High$314.00

Analyst Target Range

Forward P/E17.0x
(Fair)
PEG Ratio0.98
(Undervalued)
Implied Growth+7.5%
(Low)
Analyst Spread33.6%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$188.63
Consensus$264.86
High$314.00
Low$225.00

Consensus Scenario Assumptions

The base valuation assumes RMD achieves its forward estimates and maintains a stable P/E multiple of 17.0x. This scenario reflects the blended consensus of 35 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 35 published analyst recommendations for RMD

43% hold / mixed conviction
+14
BearishBullish
Weighted analyst sentiment score based on 35 ratings
ConsensusBuy
Coverage35 Analysts
Net Score+14
Bull / Bear43% / 14%
Strong Buy00%
Buy1543%
Hold1543%
Sell514%
Strong Sell00%
Strong Buy
00%
Buy
1543%
Hold
1543%
Sell
514%
Strong Sell
00%
Recommendation Mix43% Buy · 43% Hold · 14% Sell
Buy (15)Hold (15)Sell (5)

RMD Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, ResMed Inc. (RMD) has a Wall Street consensus price target of $264.86, based on estimates from 35 covering analysts. With the stock currently trading at $188.63, this represents a potential upside of +40.4%. The company has a market capitalization of $27.48B.

Analyst price targets range from a low of $225.00 to a high of $314.00, representing a 34% spread in expectations. The median target of $265.00 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,15 rating it Hold, and 5 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, RMD trades at a trailing P/E of 19.8x and forward P/E of 17.0x. The forward PEG ratio of 0.98 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +7.5% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $236.83, with bear and bull scenarios of $149.21 and $312.05 respectively. Model confidence stands at 62/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+48.0%
Industry Consensus
Avg Forward P/E
19.3x
(Fair)
Peers with Coverage
9 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
PHG logo
PHGKoninklijke Philips N.V.
$25.5B$26.78——Hold17.1x22
ITGR logo
ITGRInteger Holdings Corporation
$3.1B$90.96$108.00
+18.7%
Buy15.0x15
NVCR logo
NVCRNovoCure Limited
$1.6B$14.28$33.00
+131.1%
Buy—15
INSP logo
INSPInspire Medical Systems, Inc.
$1.2B$42.61$57.36
+34.6%
Hold47.5x27
TNDM logo
TNDMTandem Diabetes Care, Inc.
$1.0B$15.30$31.40
+105.2%
Buy—39
MDT logo
MDTMedtronic plc
$101.9B$79.34$95.80
+20.7%
Buy13.3x51
SYK logo
SYKStryker Corporation
$117.9B$307.80$387.46
+25.9%
Buy20.5x51
BSX logo
BSXBoston Scientific Corporation
$67.3B$45.29$82.90
+83.0%
Buy13.5x44
ZBH logo
ZBHZimmer Biomet Holdings, Inc.
$17.2B$87.97$96.33
+9.5%
Hold10.4x42
HOLX logo
HOLXHologic, Inc.
$17.0B$76.01$78.69
+3.5%
Hold17.2x42

RMD — Frequently Asked Questions

Quick answers to the most common questions about buying RMD stock.

What is the RMD stock price target for 2026?

The consensus Wall Street price target for RMD is $264.86, representing 40.4% upside from the current price of $188.63. With 35 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is RMD a buy, sell, or hold?

RMD has a consensus rating of "Buy" based on 35 Wall Street analysts. The rating breakdown is mixed, with 15 Hold ratings making up the largest segment. The consensus 12-month price target of $264.86 implies 40.4% upside from current levels.

Is RMD stock overvalued or undervalued?

With a forward P/E of 16.9769x, RMD trades at a relatively low valuation. The consensus target of $264.86 implies 40.4% appreciation, suggesting meaningful undervaluation.

How high can RMD stock go?

The most bullish Wall Street analyst has a price target of $314 for RMD, while the most conservative target is $225. The consensus of $264.86 represents the median expectation. Our quantitative valuation model projects a bull case target of $312 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover RMD stock?

RMD is heavily covered by Wall Street, with 35 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 15 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the RMD stock forecast?

The 12-month RMD stock forecast based on 35 Wall Street analysts shows a consensus price target of $264.86, with estimates ranging from $225 (bear case) to $314 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $237, with bear/bull scenarios of $149/$312.

What is RMD's fair value based on fundamentals?

Our quantitative valuation model calculates RMD's fair value at $237 (base case), with a bear case of $149 and bull case of $312. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 62/100.

What is RMD's forward P/E ratio?

RMD trades at a forward P/E ratio of 17.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy RMD stock?

Wall Street analysts are very optimistic on RMD, with a "Buy" consensus rating and $264.86 price target (40.4% upside). 15 of 35 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do RMD price targets vary so much?

RMD analyst price targets range from $225 to $314, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $264.86 consensus represents the middle ground. Our model's $149-$312 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into RMD consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare